Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis

World Journal of Gastroenterology

Volumn 20, Issue 22, 2014, Pages 7011-7018

  García Compeán, Diego ^a   Jáquez Quintana, Joel Omar ^a   Lavalle González, Fernando Javier ^a   González González, José Alberto ^a   Muñoz Espinosa, Linda Elsa ^a   Villarreal Pérez, Jesús Zacarías ^a   Maldonado Garza, Héctor J ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Diabetes mellitus; Glucose metabolism disorders; Liver cirrhosis; Oral glucose tolerance test; Survival

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; CREATININE; INSULIN; ORAL ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AGE; ARTICLE; BACTERIAL PERITONITIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHILD PUGH SCORE; CHRONIC LIVER FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; ESOPHAGUS HEMORRHAGE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; ORAL GLUCOSE TOLERANCE TEST; PROSPECTIVE STUDY; SURVIVAL RATE; AGED; ASYMPTOMATIC DISEASE; BLOOD; CHI SQUARE DISTRIBUTION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME;

ADULT; AGED; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84902152345     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i22.7011     Document Type: Article

References (48)

1. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-834 [PMID: 17904449 DOI: 10.1016/j.amjmed.2007.03.025]
2. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-627 [PMID: 8119686 DOI: 10.1002/hep.1840190312]
3. Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998; 28: 141-149 [PMID: 9657106 DOI: 10.1002/ hep.510280119]
4. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010; 55: 560-578 [PMID: 20101463 DOI: 10.1007/s10620-009-1081-0]
5. Blendea MC, Thompson MJ, Malkani S. Diabetes and Chronic liver disease: Etiology and pitfalls in monitoring. Clin Diabetes 2010; 28: 139-144 [DOI: 10.2337/diaclin.28.4.139]
6. Porepa L, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010; 182: E526-E531 [PMID: 20566726 DOI: 10.1503/cmaj.092144]
7. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013; 43: 51-64 [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x]
8. García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann Hepatol 2009; 8: 13-20 [PMID: 19221528]
9. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-681 [PMID: 12100613 DOI: 10.1046/j.1440-1746.2002.02755.x]
10. Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990; 8: 29-36 [PMID: 2153513 DOI: 10.1016/0168-8227(90)90093-9]
11. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-743 [PMID: 17327353 DOI: 10.2337/dc06-1539]
12. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-125 [PMID: 8020880]
13. Lonardo A, Carulli N, Loria P. HCV and diabetes. A twoquestion-based reappraisal. Dig Liver Dis 2007; 39: 753-761 [PMID: 17611176]
14. Quintana JO, García-Compean D, González JA, Pérez JZ, González FJ, Espinosa LE, Hernández PL, Cabello ER, Villarreal ER, Rendón RF, Garza HM. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011; 10: 56-62 [PMID: 21301011]
15. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006; 40: 68-76 [PMID: 16340637 DOI: 10.1097/01.mcg.0000190774.91875.d2]
16. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756-761 [PMID: 10332677 DOI: 10.2337/diacare.22.5.756]
17. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822-1828 [PMID: 12055590 DOI: 10.1053/gast.2002.33650]
18. García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, Reyes-Cabello E, González-González JA, Muñoz-Espinosa LE, Vázquez-Elizondo G, Villarreal-Pérez JZ, Maldonado-Garza HJ. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol 2012; 11: 240-248 [PMID: 22345342]
19. Cacciatore L, Cozzolino G, Giardina MG, De Marco F, Sacca L, Esposito P, Francica G, Lonardo A, Matarazzo M, Varriale A. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res 1988; 7: 185-188 [PMID: 3402168]
20. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N, Hayashi N, Hori M. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-75 [PMID: 16405536 DOI: 10.1111/j.1572-0241.2005.00307.x]
21. Cozzolino G, Lonardo A, Francica G, Amendola F, Cacciatore L. Differential diagnosis between hepatic cirrhosis and chronic active hepatitis: specificity and sensitivity of physical and laboratory findings in a series from the Mediterranean area. Am J Gastroenterol 1983; 78: 442-445 [PMID: 6869354]
22. Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, Schulzer M, Mak E, Yoshida EM. Does this patient with liver disease have cirrhosis? JAMA 2012; 307: 832-842 [PMID: 22357834 DOI: 10.1001/jama.2012.186]
23. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669 [PMID: 10051466 DOI: 10.1002/hep.510290347]
24. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553 [PMID: 9686693]
25. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39: 1-7 [PMID: 20202574 DOI: 10.1016/j.gtc.2009.12.014]
26. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649 [PMID: 4541913 DOI: 10.1002/bjs.1800600817]
27. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805 [PMID: 17326206 DOI: 10.1002/hep.21563]
28. Cox D. Regression models and life tables. J Roy Statist Soc 1972; 34: 187-220
29. Petrasch S, Stein H, Kosco MH, Brittinger G. Follicular dendritic cells in non-Hodgkin lymphomas: localisation, characterisation and pathophysiological aspects. Eur J Cancer 1991; 27: 1052-1056 [PMID: 1832893 DOI: 10.1016/ S0140-6736(08)60383-9]
30. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-889 [PMID: 17402991 DOI: 10.1111/j.1365-2036.2007.03246.x]
31. Tellez-Avila FI, Sanchez-Avila F, García-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda-Contreras E, Uribe M. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14: 4771-4775 [PMID: 18720537 DOI: 10.3748/wjg.14.4771]
32. Taura N, Ichikawa T, Hamasaki K, Nakao K, Nishimura D, Goto T, Fukuta M, Kawashimo H, Fujimoto M, Kusumoto K, Motoyoshi Y, Shibata H, Abiru N, Yamasaki H, Eguchi K. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006; 101: 2752-2759 [PMID: 17026566 DOI: 10.1111/ j.1572-0241.2006.00835.x]
33. Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int 2010; 30: 356-364 [PMID: 20040049 DOI: 10.1111/j.1478-3231.2009.02185.x]
34. Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-348 [PMID: 16932311 DOI: 10.1038/ncpendmet0190]
35. Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000; 12: 677-681 [PMID: 10843744 DOI: 10.1006/cyto.1999.0660]
36. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin--a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280 [PMID: 16634986 DOI: 10.1111/j.1463-1326.2005.00510.x]
37. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008; 15: 91-101 [PMID: 18602801 DOI: 10.1016/j.pathophys.2008.05.001]
38. Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, Tilg H. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005; 43: 929-936 [PMID: 16139921 DOI: 10.1016/j.jhep.2005.05.030]
39. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, Macarri G, Perego L, Benedetti A, Folli F. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-1751 [PMID: 10347117 DOI: 10.1002/hep.510290632]
40. Hagel S, Bruns T, Herrmann A, Stallmach A, Schmidt C. Abnormal glucose tolerance: a predictor of 30-day mortality in patients with decompensated liver cirrhosis. Z Gastroenterol 2011; 49: 331-334 [PMID: 21391163 DOI: 10.1055/ s-0029-1245933]
41. Sorrentino P, Tarantino G, Conca P, Perrella A, Perrella O. Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome. Can J Gastroenterol 2004; 18: 381-386 [PMID: 15190393]
42. Cheruvattath R, Balan V. Infections in Patients With Endstage Liver Disease. J Clin Gastroenterol 2007; 41: 403-411 [PMID: 17413611 DOI: 10.1097/01.mcg.0000248018.08515.f9]
43. Moreau R, Chagneau C, Heller J, Chevenne D, Langlet P, Deltenre P, Hillaire S, Lefilliatre P, Pateron D, Sogni P, Valla D, Lebrec D. Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cirrhosis receiving glucose. Scand J Gastroenterol 2001; 36: 303-308 [PMID: 11305519 DOI: 10.1080/003655201750074654]
44. Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54: 556-563 [PMID: 15753544 DOI: 10.1136/gut.2004.048181]
45. Kalaitzakis E, Olsson R, Henfridsson P, Hugosson I, Bengtsson M, Jalan R, Björnsson E. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. Liver Int 2007; 27: 1194-1201 [PMID: 17919230]
46. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, Zoli M, Melchionda N. Cardiovascular disease in cirrhosis--a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999; 94: 655-662 [PMID: 10086647]
47. Petta S, Torres D, Fazio G, Cammà C, Cabibi D, Di Marco V, Licata A, Marchesini G, Mazzola A, Parrinello G, Novo S, Licata G, Craxì A. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 2012; 55: 1317-1323 [PMID: 22135089 DOI: 10.1002/hep.25508]
48. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCVrelated steatosis. Atherosclerosis 2012; 221: 496-502 [PMID: 22385985 DOI: 10.1016/j.atherosclerosis.2012.01.051]